Promotional material

Vaccine update: issue 365, November 2025

Published 26 November 2025

Applies to England

Chickenpox joins the routine schedule

Starting 1 January 2026, the NHS is adding varicella (chickenpox) to the standard childhood vaccination schedule. Instead of the familiar MMR vaccine (measles, mumps, rubella), children will now be offered a four-in-one vaccine: measles, mumps, rubella and varicella (chickenpox).

This move follows recommendations from the Joint Committee on Vaccination and Immunisation (JCVI) and is designed to reduce incidence of varicella infection and the serious complications which can follow. Varicella (chickenpox) is a common childhood infection and most children will recover in a few weeks, but it can cause serious complications for some children and vulnerable adults, particularly pregnant women. By rolling out the MMRV vaccine, the NHS aims to reduce transmission, protect children from illness, giving them the best protection and to support parents who would otherwise miss work to care for children while they were unwell.

For further details please see the routine immunisation schedule and the Introduction of a routine varicella (MMRV) vaccination programme letter.

What’s changing in the Routine Programme

Babies born on or after 1 January 2025:

• 2 doses of the new MMRV vaccine
• first at 12 months
• second at 18 months

Toddlers born between July and December 2024:

• MMR at 12 months
• then MMRV at 18 months
• and again at 3 years 4 months

Children born September 2022 to June 2024:

• 1 dose of MMRV at 3 years 4 months (instead of MMR)

Older children (born January 2020 to August 2022):

• Eligible for a special catch-up programme if they haven’t had chickenpox or the vaccine.

Catch-Up Programme

Between November 2026 and March 2028, children aged 3 years 4 months up to under 6 years (as of December 2025) will be offered a single dose of MMRV if they’ve never had chickenpox or the vaccine.

All eligible children should be invited by their GP, there is no requirement for GPs to check whether children have had chickenpox before providing the vaccine when parents respond to this offer.

The vaccines

Two versions of the combined vaccine will be used:

• ProQuad
• Priorix Tetra

They’re clinically equivalent, but Priorix-Tetra® may be preferred for families requesting an alternative that does not contain porcine gelatine. See more information on vaccines and porcine gelatine.

Note: the NHS won’t be offering a chickenpox-only vaccine, and the old MMR vaccine will be phased out of the routine childhood programme. MMR will remain available to order for vaccinating older cohorts and adults who have missed MMR vaccination.

Main takeaways

• from 2026, MMRV replaces MMR in the routine childhood schedule
• chickenpox protection is now standard for babies and toddlers
• a catch-up programme ensures older preschoolers don’t miss out
• there are no safety concerns if a child gets the vaccine after already having chickenpox

For more information see: MMRV vaccination: information for healthcare professionals

Cover data

The Cover of Vaccination Evaluated Rapidly (COVER) programme evaluates childhood immunisation in England, collating data for children aged 1, 2 and 5. Data is collected by financial year. Vaccination coverage statistics quarterly data tables are provisional and give an indication of current coverage.

Vaccination coverage statistics for children aged up to 5 years, England (COVER programme) report

The latest annual COVER statistics show mixed trends in childhood vaccination coverage across the UK. At 12 months, uptake rose slightly for the 6 in 1, rotavirus, and MenB vaccines, while PCV coverage dipped marginally. By 24 months, coverage for most vaccines remained stable or saw very small declines, with Scotland and Wales maintaining rates above 92% and Northern Ireland above 87%.

At age 5, overall UK coverage for the 6 in 1 edged up to 93.2%, but the pre school booster (dTaP/IPV) fell sharply by 1.2%, and MMR2 dropped slightly. Scotland and Wales exceeded the WHO’s 95% target for the 6 in 1 and MMR1, while Northern Ireland achieved strong results just below that threshold. In England, coverage varied by region, with London consistently reporting the lowest rates.

This report also marks the UK Health Security Agency’s first publication of the annual COVER statistics, now hosted on its updated dashboard.

Read the full report.

Quarterly vaccination coverage statistics for children aged up to 5 years in the UK (COVER programme): April to June 2025

The latest quarterly COVER report, covering April to June 2025, shows small but consistent declines in vaccination coverage across the UK compared with the previous quarter.

At 12 months of age, uptake fell slightly for several important vaccines: the 6 in 1 (down 0.4 percentage points to 91.4%), PCV (down 0.2 points to 93.3%), rotavirus (down 0.3 points to 89.4%), and MenB (down 0.3 points to 91.4%). England mirrored these declines, with London continuing to report the lowest coverage nationally. Uptake of the first dose of MMR at 24 months fell by 0.3 points in both England and the UK, while coverage of the first dose of MMR at age 5 dropped by 0.4 points in England. Pre school boosters (dTaP/IPV) and the second dose of MMR also saw larger decreases of 1.2 points, reflecting vaccinations due in late 2023.

Despite these declines, Scotland and Wales exceeded the World Health Organization’s 95% target for both the 6 in 1 and MMR1 vaccines at age 5, while Northern Ireland achieved at least 94% coverage. Regional variation remains significant: outside London, England’s coverage rates were consistently higher, with the South West even showing a small increase in 6 in 1 uptake. Overall, however, vaccination coverage continues to sit below the peaks seen over the past decade, and the downward trend across several antigens highlights ongoing challenges in maintaining high levels of protection against preventable diseases.

Read the full report.

Pertussis coverage

This quarterly report evaluates prenatal pertussis vaccine coverage for women who delivered from April 2025 to June 2025, the first quarter of the 2025 to 2026 financial year.

The main findings were that:

• coverage was 72.2% in April 2025, 71.2% in May 2025 and 70.2% in June 2025
• coverage for quarter 1 was 71.2%, which was 11.6 percentage points higher than quarter 1 coverage in the previous financial year
• coverage by Commissioning Region ranged from 63.7% in London to 78.2% in the South West

Note: A new point of care app developed by NHSE to record vaccination events was introduced in September 2024. The Record a Vaccination service (RAVs) has improved dataflows into general practice which may partially account for the increase in coverage reported in recent months.

See: Prenatal pertussis vaccination coverage in England: April to June 2025.

Meningococcal disease: Annual report

The latest UKHSA report on invasive meningococcal disease (IMD) shows that England recorded 378 confirmed cases in the 2024/25 epidemiological year, up from 340 the year before but still below pre-pandemic levels. The majority of cases were caused by group B meningococcal disease (MenB), which accounted for over 82% of infections and was particularly dominant among children and young adults under 25. While MenB remains the leading strain, cases of MenW rose to 43, linked to recent travel to the Middle East, though numbers remain lower than the peaks seen before 2020. MenC and MenY cases stayed very low, reflecting the success of vaccination programmes. Despite the overall decline in IMD over the past two decades, the provisional case fatality rate in 2024/25 was 8.2%, highlighting the seriousness of the disease.

Vaccination continues to play a critical role in controlling IMD. Infant coverage for the MenB vaccine remains high, with over 90% receiving two doses by 12 months, while the MenACWY teenage programme has provided strong herd protection against other strains. However, uptake among adolescents is still below optimal levels, with coverage around 72 to 73% in school years 9 and 10. Public health officials stress the importance of encouraging teenagers and young adults, particularly those entering higher education, to get vaccinated, as they face higher risks of infection. Resources from UKHSA and meningitis charities are available to support awareness of symptoms and the need for early medical intervention.

See the full report: Meningococcal disease: laboratory-confirmed cases in England 2024 to 2025.

RSV older adults vaccine coverage

The respiratory syncytial virus (RSV) vaccination programme was introduced in September 2024. The routine programme offers the vaccine to those turning 75 and patients remain eligible for the vaccine until their 80th birthday. This report evaluates vaccine coverage in the catch-up cohorts aged 75 to 79 years old before 1 September 2024 and until 31 August 2025, assessed at the end of August 2025.

The main conclusion is that as of 31 August 2025, the overall vaccine coverage in the catch-up cohort (adults aged 75 to 79 before the programme start date) reached 64.8%, up from the 63.4% reported in the July 2025 report.

See the full report: RSV vaccine coverage report in older adults in England: September 2025.

RSV maternal vaccine coverage

The main messages of this report are:

• 53.7% (20,745 out of 38,642) of women that reported giving birth during the survey month received an RSV vaccine
• coverage varied by NHS commissioning region, with the highest coverage reported in the South West region (62.6%) and the lowest in the London region (46.3%) coverage varied by ethnic group, with the highest coverage reported among Other ethnic group – Chinese (68.4%) and the lowest among Black or Black British – Caribbean (31.3%)

Maternal uptake of the RSV vaccine is assessed monthly to monitor the reach and impact of the national immunisation programme. Given the programme’s design, uptake is defined as the proportion of pregnant women who delivered in the reporting month and had received the RSV vaccine during pregnancy. This metric serves as a proxy for vaccine coverage by infant birth month, reflecting the extent of passive immunity conferred to newborns.

The monthly uptake trend among pregnant women who have delivered since the programme’s launch, alongside the total number of GP practice data, is presented in Figure 1. This trend shows that uptake increased in the first few months of the programme and has remained stable since January 2025.

See the full report: RSV maternal vaccination coverage in England.

Find Public Health Resources winter holiday hours

Ordering via phone will not be available from 2pm on 24th December until 9am on 3rd January. Any urgent queries relating to the vaccination programme publications deliveries can be sent via email to publichealthresources@ukhsa.gov.uk.

You can still place orders on the website as normal by visiting Find Public Health Resources.

Evri Last dates for delivery of resources

Guaranteed Christmas Deliveries:

• Friday 19th December – Standard
• Monday 22nd December – Next Day

Childhood vaccines parental attitudes survey 2025

The UK Health Security Agency (UKHSA) designed an online survey to find out what parents of children aged 2 months to 4 years think about vaccination. UKHSA commissioned the commercial research organisation, IPSOS, to undertake the survey on their behalf.

• download a spreadsheet of the survey data
• download a slide set of the survey findings

See the full survey findings.

Immunisation against infectious disease (the Green Book) Chapter 2: Consent

This chapter has been revised to include the Care Quality Commission position on consent to treatment, clarification on who may seek consent to vaccination and information on consent in those under 16 years of age, disagreement between parents and delivery of vaccination in schools.

See the full chapter.

Updated vaccination timeline

A new version has been redesigned and updated and is available to view and download.

Updated BCG pathways

Both the BCG vaccination and SCID screening: patient pathway and the BCG vaccination and SCID screening: data pathway have been updated and are available for download and use.

Vaccine supply

Routine vaccination programme

Attention all ImmForm customers: Christmas and New Year holiday deliveries

Due to Christmas and New Year holidays, there will be no deliveries or order processing by Movianto on Thursday 25 and Friday 26 December 2025, nor on Thursday 1 January 2026. See the table below for your revised order and delivery days, and the additional information for offshore customers.

All customers should prepare for this break in deliveries and order accordingly. Ensure you have enough room in your fridge for any additional vaccine that you order in advance of this holiday period, bearing in mind the recommendation that only two to four weeks of vaccine stock should be held locally.

Please be advised that no emergency or out of schedule deliveries can be arranged for ImmForm customers who fail to place their orders by the cut-off date and time.

Delivery date	Order cut-off date	Order cut-off time	Notes / holidays
Wednesday 24 December 2025	Monday 22 December 2025	11:55 am
Thursday 25 December 2025			No deliveries or order processing
Friday 26 December 2025			No deliveries or order processing
Monday 29 December 2025	Tuesday 23 December 2025	11:55 am
Tuesday 30 December 2025	Wednesday 24 December 2025	11:55 am
Wednesday 31 December 2025	Monday 29 December 2025	11:55 am
Thursday 1 January 2026			No deliveries or order processing
Friday 2 January 2026	Tuesday 30 December 2025	11:55 am	No deliveries to Scotland customers
Monday 5 January 2026	Wednesday 31 December 2025	11:55 am
Tuesday 6 January 2026	Friday 2 January 2026	11:55 am
Wednesday 7 January 2026	Monday 5 January 2026	11:55 am
Thursday 8 January 2026	Tuesday 6 January 2026	11:55 am
Friday 9 January 2026	Wednesday 7 January 2026	11:55 am

Offshore customers:

• Isle of Wight and Isle of Man: See the table above for your revised order and delivery days
• Jersey, Guernsey, Shetland, Stornoway and Orkney: No deliveries will be made after Tuesday 23 December 2025 until Wednesday 7 January 2026.

See the table above for our revised order and delivery days.

COVID-19 and mpox vaccine offshore customers:

• Guernsey, Jersey, Isle of Man and Scottish islands: The final orders before Christmas will be handed to the courier on Monday 22 December 2025 for the final mile delivery on Tuesday 23 December 2025. The first delivery after Christmas will be handed to the courier on Monday 29 December 2025 for the final mile delivery on Tuesday 30 December 2025

Introduction of a combined measles, mumps, rubella and varicella (MMRV) vaccine

From 1 January 2026, the NHS routine childhood vaccination programme will include a combined measles, mumps, rubella and varicella (MMRV) vaccine. See more details about the introduction of MMRV vaccination.

From 1 January 2026, the current MMR vaccines (M‑M‑RvaxPro® and Priorix®) will continue to be available to order via ImmForm for administration outside of the routine childhood programme, for example, for vaccination of older individuals, that is, those born on or before 31 December 2019, who have not received two doses of MMR and are not eligible for MMRV.

ProQuad® and Priorix-Tetra® will be the vaccines used for the MMRV programme. ProQuad® and Priorix-Tetra® vaccines will be available for ImmForm customers in England and Wales to order from Monday 1 December 2025. ProQuad® vaccine should be ordered for all MMRV vaccinations, unless a patient requires a porcine gelatine-free MMRV vaccine. ImmForm customers in England and Wales may order ProQuad® vaccine with only a high-level ordering control in place to reduce the risk of ordering errors only. This is not intended to restrict activity.

In addition, ImmForm customers in England and Wales may order up to 10 porcine gelatine-free Priorix-Tetra® doses per account per week. Please note there are 10 Priorix-Tetra® doses in each vaccine pack ordered via ImmForm. Scottish customers should refer to local ordering guidance.

ProQuad® vaccine ordered via ImmForm will be supplied as a single-dose pack, containing one pre-filled syringe, one vial of solvent for reconstitution, one patient information leaflet (PIL), and two unattached non-safety needles. One needle should be used for reconstitution and a separate, new needle for injection.

See more details about ProQuad® vaccine

Priorix-Tetra® vaccine ordered via ImmForm will be supplied as a 10-dose pack, containing 10 single-dose vials (10 x 0.5 ml) of vaccine, 10 single-dose vials of diluent and one patient information leaflet (PIL). Each 10-dose pack of Priorix-Tetra® vaccine ordered via ImmForm will also be supplied with a pad of 10 additional PILs. Priorix-Tetra® vaccine supplied via ImmForm does not contain needles for administration.

Further details about Priorix-Tetra® vaccine can be found here: Priorix Tetra

Further guidance on the choice of needle size can be found in the Green Book: Chapter 4. Needles should be obtained locally.

To help with planning storage requirements: - the dimensions of each single-dose pack of ProQuad® vaccine are 150 x 47 x 28 mm (H x W x D) - the dimensions of each larger ten-dose pack of Priorix-Tetra® vaccine are 142 x 178 x 29 mm (H x W x D)

To minimise wastage due to fridge failures, please order no more than two to four weeks’ worth of stock. Further guidance can be found in the Green Book: Chapter 3.

Contact the helpdesk@immform.org.uk for ordering queries.

Changes to the routine childhood vaccination schedule since 1 July 2025

The routine childhood vaccination schedule changed on 1 July 2025. All vaccines required to support the routine childhood vaccination schedule remain available to order by ImmForm.

Providers should note that whilst Menitorix® is no longer offered to children turning one year old from 1 July 2025 onwards, Menitorix® will remain available to order by ImmForm for those children previously eligible for it. Once central supplies of Menitorix® deplete, those previously eligible children should be offered a dose of DTaP/Hib/IPV/HepB vaccine, also available by ImmForm.

See more details of the changes to the routine immunisation schedule.

Meningococcal B (Men B) vaccination for protection against gonorrhoea

Since 1 August 2025, Meningococcal B (Men B) vaccination for protection against gonorrhoea is being offered by specialist sexual health services, primarily for gay, bisexual and other men who have sex with men (GBMSM).

Bexsero® (Men B) vaccine is available for sexual health services in England and Wales to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland should refer to their local ordering restrictions.

For customers that also access Bexsero® for the infant immunisation programme, when ordering Bexsero®, orders should be placed for the ImmForm product that is specific to the programme for which the stock is intended. Bexsero® ordered for the infant immunisation protection programme should not be used for the GBMSM gonorrhoea protection programme and vice versa.

Bexsero® vaccine ordered via ImmForm is supplied as a ten-dose pack, containing ten pre-filled syringes of vaccine and one patient information leaflet (PIL). Each 10-dose pack of Bexsero® vaccine ordered via ImmForm is supplied with a pad of 10 additional PILs.

The 10-dose pack of Bexsero® vaccine supplied by ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book chapter 4. Needles should be obtained locally.

Please add Bexsero® vaccine to your routine ImmForm order where possible, rather than creating additional orders.

To minimise wastage due to fridge failures, order no more than 2 to 4 weeks’ worth of stock.

Details about meningococcal B (Men B) vaccination for use against gonorrhoea can be found in the on the Men B guidance leaflet.

Further details about Bexsero® vaccine can be found in the patient information leaflet (PIL).

Contact the helpdesk@immform.org.uk for ordering queries.

Routine mpox vaccination programme

Since summer 2025, a routine mpox vaccination programme is being offered by specialist sexual health services, primarily for gay, bisexual and other men who have sex with men (GBMSM).

Imvanex® (mpox) vaccine is available for Scotland Health Boards, and sexual health services in England and Wales to order via ImmForm. High-level ordering controls are in place to reduce the risk of ordering errors only. These are not intended to restrict activity. ImmForm customers in Scotland should refer to their local ordering restrictions.

Imvanex® vaccine ordered via ImmForm is supplied as a 10-dose pack, containing 10 vials (10 x 0.5 ml) of vaccine and one patient information leaflet (PIL). Each 10-dose pack of Imvanex® vaccine ordered via ImmForm is supplied with a pad of 10 additional PILs and a Dear Healthcare Professionals (DHCP) letter explaining the provision of a non-UK licensed pack.

Imvanex® vaccine ordered via ImmForm is delivered to customers on their routine weekly delivery day, in an isothermic shipper with an internal temperature of –20°C. The isothermic shipper is recycled by Movianto who will either retain the shipper at the time of delivery to ImmForm customers or arrange for its collection on a later date. ImmForm customers should therefore not dispose of the isothermic shipper.

Upon receipt on Imvanex® vaccine ordered via ImmForm, customers can continue to store the Imvanex® vaccine at –20°C to retain the –20°C expiry shown on the delivery note and pack. Alternatively, customers can store Imvanex® vaccine at +2 to +8°C, with the vaccine then having an expiry date of 8 weeks from the time when the vaccine was removed from its –20°C storage.

The 10-dose pack of Imvanex® vaccine supplied by ImmForm does not contain needles for administration. Guidance on the choice of needle size can be found in the Green book, chapter 4. Needles should be obtained locally.

To help with planning storage requirements, the dimensions of the 10-dose pack of Imvanex® vaccine are 54 x 38 x 92mm (H x W x D). Please see the Storage, distribution and disposal of vaccines: the green book, chapter 3 for further guidance .

To minimise wastage due to fridge failures, order no more than 2 to 4 weeks’ worth of stock.

Details about mpox vaccination can be found at in the programmes letter. Additional programme resources are available at Vaccination against mpox.

Further details about Imvanex® vaccine can be found in the manufacturer’s Summary of product characteristics (SmPC)

Contact the helpdesk@immform.org.uk for ordering queries.

Vaccines for the 2025 to 2026 children’s flu programme supplied by UKHSA

All flu vaccines for the 2025/26 children’s flu programme are available to order by general practice and school-age providers in England via ImmForm.

Community pharmacies who are delivering flu vaccinations to 2 and 3 year olds can access Fluenz® (LAIV) via the Federated Data Platform (FDP) managed by NHS England. Vaccines for this service will not be available to order through ImmForm. UKHSA does not supply any flu vaccines for patients aged 18 years and over.

Please refer to guidance from your respective health departments for arrangements in Scotland, Wales and Northern Ireland.

Expiry dates for all batches of Fluenz® issued for the 2025 to 2026 children’s flu programme

Batch numbers and associated expiry dates of all batches of Fluenz® that either have or will be issued this season are set out in the table below. Please ensure that the expiry date is always checked before use, and that expired stock is disposed of in line with local policies. Any disposed stock should be recorded through the ImmForm stock incident page.

Batch number	Expiry date	Batch number	Expiry date
YF2962	9 December 2025	YK2680B	5 January 2026
YF2962B	9 December 2025	YK2763	6 January 2026
YF2965	10 December 2025	YK2682	12 January 2026
YF2965B	10 December 2025	YK2682B	12 January 2026
YF2963	15 December 2025	YK2998	19 January 2026
YF3265	15 December 2025	YL2477	2 February 2026
YF3265B	15 December 2025	YL2477B	2 February 2026
YF2964	16 December 2025	YM2013B	9 February 2026
YF3276	16 December 2025	YL2672	16 February 2026
YH2667	22 December 2025	YL2672B	16 February 2026
YH2667B	22 December 2025	YM2014	23 February 2026
YF3414	29 December 2025	YL2671	2 March 2026
YF3414B	29 December 2025	YL2671B	30 March 2026
YK2680	5 January 2026

Vaccines and availability

The 2 vaccines that will be available, preliminary indicative ordering dates and the groups that these vaccines should be ordered for are set out in the table below.

Vaccine	Manufacturer	Available to order for
Fluenz® (LAIV)	AstraZeneca	All children from 2 years of age to school year 11
Children in clinical risk groups aged from 2 up to their 18th birthday [note 1]
Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc)	Seqirus	Children in clinical risk groups aged from 6 months up to their 2nd birthday
All other eligible [note 2] children aged from 2 up to their 18th birthday for whom LAIV is unsuitable

Note 1: Unless LAIV clinically contraindicated or otherwise unsuitable.

Note 2: Children from 2 years of age to school year 11, and children in clinical risk groups aged 2 to less than 18 years.

LAIV ordering information for general practice

Ordering controls will be in place for general practices, to enable UKHSA to balance supply with demand. These controls will work by allocating an amount of LAIV based on the umber of registered eligible patients and will be tailored to each practice.

• each GP practice will initially be allocated sufficient LAIV to vaccinate at least 45% of its eligible patients (all 2 and 3 year olds, plus children in clinical risk groups from age 4 to less than 18 years) when ordering commences
• increases to these allocations will be made in response to demand and vaccine availability
• requests for extra vaccine will be considered on a case-by-case basis throughout the ordering period – requests for additional vaccine should be sent to the helpdesk (helpdesk@immform.org.uk) and should be sent in good time before your order cut-off
• out-of-schedule deliveries will be by exception only

This vaccine has a short shelf life. Try to hold no more than 2 weeks’ stock at a time and re-order regularly to reduce local wastage through expiry before use.

LAIV ordering information for school-age providers

LAIV ordering information for school-age providers School providers are able to place 2 orders and receive 2 deliveries of LAIV per week, to assist in the management of vaccine volumes required across limited storage space at delivery points.

This operates on a 48-hour delivery schedule requiring the order to be placed before the 11.55am cut-off 2 working days before the required delivery day. The table below illustrates the respective delivery days versus ordering day.

Order day (before 11.55am cut off)	Delivery day
Monday	Wednesday
Tuesday	Thursday
Wednesday	Friday
Thursday	Monday
Friday	Tuesday

Customers must ensure that the point of delivery will be open and staffed between 9am and 5pm on the delivery day when placing orders.

Please note that this does not affect the routine ordering and delivery schedule of any other vaccines (including inactivated flu vaccines) ordered from ImmForm and is applicable to Fluenz® (LAIV) only.

A default weekly ordering cap of 450 packs (4,500 doses) per week is in place for school provider accounts. Where this cap is insufficient and a provider needs a larger weekly volume of vaccine to deliver the programme (for example where a provider covers a large area using a single account), a higher weekly cap should be requested via the UKHSA Flu Vaccine Operations team by emailing childfluvaccine@ukhsa.gov.uk and providing your ImmForm account number or Org code.

For one-off larger orders during the ordering period, requests should be made via helpdesk@immform.org.uk.

Inactivated flu vaccine ordering

The Cell Based Trivalent Influenza Vaccine (Surface Antigen, Inactivated) (TIVc) will be available to order, in a single dose pack, for:

• children in clinical risk groups aged from 6 months to less than 2 years old
• children aged from 2 to less than 18 years old in clinical risk groups for whom LAIV is clinically contraindicated or otherwise unsuitable
• healthy children from 2 years old to those in school year 11, for whom LAIV is unsuitable (for example, due to objection to LAIV on the grounds of its porcine gelatine content)

Order controls will also be in place for this vaccine as follows:

• for GPs, there will be an initial cap of 10 doses/packs per week
• for school-age providers, there will be a cap of 450 doses/packs per week

Influenza vaccines for the 2025 to 2026 season

Information on all influenza vaccines that will be marketed in the UK for the 2025 to 2026 season are available on the flu vaccination page on GOV.UK.

Place orders only for delivery on days when your site is open

ImmForm customers should place orders only for delivery on days when their site is open and able to accept the delivery. ImmForm’s deferred order function can be used to place orders for future dates when a site is open. Delivery failures because of a site being closed, create additional, unnecessary workload within the distribution network. In the case of a one-off closure, ImmForm customers should immediately re-schedule the delivery date of orders due for delivery on that day. For long-term changes to the days when a site can accept deliveries, ImmForm customers should contact their Movianto Customer Care team with details. Contact details are included on each Movianto Delivery Note. Short-term changes to delivery days cannot be made, for example, for absence or holidays.

MMR vaccine ordering

M-M-RvaxPro® vaccine should be ordered for all MMR vaccinations, unless a patient requires a porcine gelatine-free MMR vaccine. ImmForm customers in England and Wales may order M-M-RvaxPro vaccine without restriction. In addition, ImmForm customers in England and Wales may order up to ten porcine gelatine-free Priorix® vaccines per account per week. ImmForm customers in Scotland should refer to their local ordering restrictions. Both MMR vaccines may only be ordered for outbreak purposes when this is part of a national catch-up campaign

Non-routine vaccine supply

Hepatitis A vaccine

Adult

GSK: supply of Havrix Adult PFS singles and packs of 10 are currently available.

Sanofi : Avaxim PFS singles are currently available. Avaxim packs of 10 are currently available.

MSD: VAQTA Adult is available.

Paediatric

GSK: supply of Havrix Paediatric singles and packs of 10 are currently available.

MSD: VAQTA Paediatric is available.

Sanofi Pasteur: Avaxim Junior singles are currently available.

Hepatitis B vaccine

Adult

GSK: Engerix B PFS singles and packs of 10 are currently available.

GSK: supply of Fendrix is currently available.

MSD: HBVAXPRO 10μg is available.

MSD: HBVAXPRO 40μg is available.

Valneva: PreHevbri is no longer marketed in the UK.

Paediatric

GSK: supplies of Engerix B Paediatric singles are currently available.

MSD: HBVAXPRO 5μg is available.

Combined hepatitis A and B vaccine

GSK: Twinrix Adult singles and packs of 10 are available.

GSK: Twinrix Paediatric is currently available.

GSK: Ambirix is available.

Combined hepatitis A and typhoid vaccine

Sanofi: Viatim is now a discontinued product and no longer available for sale.

Typhoid vaccine

Bavarian Nordic: Vivotif is available.

Sanofi: Typhim singles and packs of 10 are available.

Rabies vaccine

Bavarian Nordic: Rabipur is currently available.

Sanofi: Verorab is available to order with some restrictions – 100 doses per month per depot for wholesalers but kept 50 doses per customer per month for all other customers

Pneumococcal polysaccharide vaccine (PPV)

MSD: Private supply of Pneumovax 23 (PPV23) PFS discontinued from October 2025

Pneumococcal polysaccharide conjugate vaccine (PCV)

Pfizer: Prevenar 13 is currently available.

Pfizer: Prevenar 20 is currently available.

MSD: Vaxneuvance is currently available.

Varicella zoster vaccine

GSK: VARILRIX is currently available.

MSD: VARIVAX is available.

MSD: ZOSTAVAX is a discontinued product.

Diphtheria, tetanus and poliomyelitis (inactivated) vaccine

Sanofi: Revaxis is available.

Diphtheria, tetanus, pertussis (acellular) and poliomyelitis (inactivated) vaccine

GSK: supply of Boostrix-IPV is currently available.

Sanofi: Repevax is currently available.

MMR vaccine

MSD: MMR VaxPro is currently available.

GSK: Priorix is currently available.

Meningitis ACWY vaccine

GSK: Menveo is currently available.

Pfizer: Nimenrix is currently available.

Sanofi: MenQuadfi is available.

Yellow fever vaccine

Sanofi: Stamaril is available to order without restrictions

Human papillomavirus vaccine

MSD: GARDASIL has been discontinued.

MSD: Gardasil 9 is currently available.

GSK: Cervarix has been discontinued.

Cholera vaccine

Bavarian Nordic: Vaxchora is available.

Valneva: Dukoral is available.

Japanese encephalytis vaccine

Valneva: Ixiaro is available.

Meningococcal group B vaccine

GSK: Bexsero is currently available.

Diphtheria, tetanus, pertussis, Hib vaccine and poliomyelitis

GSK: Infanrix IPV+Hib is currently available.

Hib + meningococcal group C combined vaccine

GSK: Menitorix is currently available.

Live attenuated rotavirus vaccine

GSK: Rotarix is currently available.

Herpes zoster vaccine

GSK: Shingrix is currently available.

Diphtheria, tetanus and pertussis

Sanofi: Adacel is currently available

Dengue tetravalent vaccine

Takeda: Qdenga is currently available.

Respiratory syncytial virus vaccine

Pfizer: Abrysvo is currently available.

GSK: Arevxy is currently available.

Chikungunya vaccine

Valneva: IXCHIQ®▼ is available. Please read important MHRA Drug Safety update on IXCHIQ® powder and solvent for solution for injection Chikungunya vaccine (live).

Bavarian Nordic: Vimkunya®▼ is available